Citation: 胡建昆, 陈心足. Treatment and Prognosis Based on Types and Stages of Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(1): 1-6. doi: 10.7507/1007-9424.20140001 Copy
1. | 胡建昆,陈心足.进展期胃癌治疗方式合理选择及评价[J].中国实用外科杂志,2011,31(8):720-722. |
2. | 胡建昆,陈心足.胃癌多学科协作诊疗模式现状[J].中国普外基础与临床杂志,2012,19(1):1-3. |
3. | Hu B,El Hajj N,Sittler S,et al.Gastric cancer:Classification,histology and application of molecular pathology[J].J Gastrointest Oncol,2012,3(3):251-261. |
4. | 何裕隆.胃癌病理分型研究进展[J].中国实用外科杂志,2005,25(7):438-440. |
5. | Santiago JM,Sasako M,Osorio J.TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer.Tow-ards simplicity and standardisation in the management of gastric cancer[J].Cir Esp,2011,89(5):275-281. |
6. | Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14(2):113-123. |
7. | Liang YX,Guo HH,Deng JY,et al.Impact of intraoperative blood loss on survival after curative resection for gastric cancer[J].World J Gastroenterol,2013,19(33):5542-5550. |
8. | Yang B,Wu G,Wang X,et al.Discussion of modifying stage Ⅳ gastric cancer based on Borrmann classification[J].Tumour Biol,2013,34(3):1485-1491. |
9. | Sun XC,Lin J,Ju AH.Treatment of Borrmann type Ⅳ gastric cancer with a neoadjuvant chemotherapy combination of docetaxel,cisplatin and 5-fluorouracil/leucovorin[J].J Int Med Res,2011,39(6):2096-2102. |
10. | Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459. |
11. | Sasako M,Sano T,Yamamoto S,et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial[J].Lancet Oncol,2006,7(8):644-651. |
12. | Mine S,Sano T,Hiki N,et al.Proximal margin length with trans-hiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction[J].Br J Surg,2013,100(8):1050-1054. |
13. | Lauren P.The two histological main types of gastric carcinoma:Diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification[J].Acta Pathol Microbiol Scand,1965,64:31-49. |
14. | Lauwers GY,Carneiro F,Graham DY.Gastric carcinoma[A]//Bowman FT,Carneiro F,Hruban RH,eds.Classification of tumours of the digestive system[M].Lyon:IARC,2010.In press. |
15. | 李忠武,曹登峰.胃癌病理分型与临床个体化治疗——问题与展望[J].中国医学前沿杂志:电子版,2012,4(5):15-20. |
16. | Liu L,Wang ZW,Ji J,et al.A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma[J].Anticancer Agents Med Chem,2013,13(2):227-234. |
17. | Qiu MZ,Cai MY,Zhang DS,et al.Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China[J].J Transl Med,2013,11:58. |
18. | Lorenzen S,Blank S,Lordick F,et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol,2012,19(7):2119-2127. |
19. | Becker K,Langer R,Reim D,et al.Significance of histopatho-logical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas:a summary of 480 cases[J].Ann Surg,2011,253(5):934-939. |
20. | Kucukoner M,Isikdogan A,Arpaci E,et al.Adjuvant chemora-diation for gastric cancer:multicentric study of the Anatolian Soc-iety of Medical Oncology[J].Hepatogastroenterology,2012,59(119):2343-2347. |
21. | Kucukoner M,Arpaci E,Isikdogan A,et al.Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy[J].Neoplasma,2013,60(1):19-25. |
22. | Yonemura Y,Ninomiya I,Yamaguchi A,et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer[J].Cancer Res,1991,51(3):1034-1038. |
23. | Kataoka Y,Okabe H,Yoshizawa A,et al.HER2 expression and its clinicopathological features in resectable gastric cancer[J].Gastric Cancer,2013,16(1):84-93. |
24. | Aizawa M,Nagatsuma AK,Kitada K,et al.Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population[J].Gastric Cancer,2013 Feb 22.[Epub ahead of print]. |
25. | Zhou F,Li N,Jiang W,et al.Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curati-vely resected gastric cancer after the ToGA clinical trial[J].World J Surg Oncol,2012,10:274. |
26. | Jorgensen JT.Targeted HER2 treatment in advanced gastric cancer[J].Oncology,2010,78(1):26-33. |
27. | Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697. |
28. | Tanner M,Hollmen M,Junttila TT,et al.Amplification of HER-2 in gastric carcinoma:association with Topoisomerase Ⅱalpha gene amplification,intestinal type,poor prognosis and sensitivity to trastuzumab[J].Ann Oncol,2005,16(2):273-278. |
29. | Fan XS,Chen JY,Li CF,et al.Differences in HER2 over-exp-ression between proximal and distal gastric cancers in the Chinese population[J].World J Gastroenterol,2013,19(21):3316-3323. |
30. | Marx AH,Tharun L,Muth J,et al.HER-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2009,40(6):769-777. |
31. | Jorgensen JT,Hersom M.HER2 as a prognostic marker in gastric cancer:a systematic analysis of data from the literature[J].J Cancer,2012,3:137-144. |
32. | Okines AF,Cunningham D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949-1959. |
33. | Okines AF,Cunningham D.Trastuzumab:a novel standard opt-ion for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer[J].Therap Adv Gastroenterol,2012,5(5):301-318. |
34. | Rüschoff J,Hanna W,Bilous M,et al.HER2 testing in gastric cancer:a practical approach[J].Mod Pathol,2012,25(5):637-650. |
35. | Sun Z,Wang ZN,Zhu Z,et al.Evaluation of the seventh edit-ion of American Joint Committee on Cancer TNM staging system for gastric cancer:results from a Chinese monoinstitutional study[J].Ann Surg Oncol,2012,19(6):1918-1927. |
36. | Reim D,Loos M,Vogl F,et al.Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer:the Western experience of patients treated in a single-center European institution[J].J Clin Oncol,2013,31(2):263-271. |
37. | Yoon HM,Ryu KW,Nam BH,et al.Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer?[J].J Am Coll Surg,2012,214(1):88-96. |
38. | Strong VE,D'Amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66. |
39. | Isomoto H,Shikuwa S,Yamaguchi N,et al.Endoscopic submu-cosal dissection for early gastric cancer:a large-scale feasibility study[J].Gut,2009,58(3):331-336. |
40. | Chen XZ,Hu JK,Yang K,et al.Short-term evaluation of lapar-oscopy-assisted distal gastrectomy for predictive early gastric cancer:a meta-analysis of randomized controlled trials[J].Surg Laparosc Endosc Percutan Tech,2009,19(4):277-284. |
41. | Chen XZ,Li YY,Hu JK,et al.Spread and development of laparoscopic surgery for gastric tumors in mainland China:initial experiences[J].Hepatogastroenterology,2012,59(114):654-658. |
42. | Wen L,Chen XZ,Wu B,et al.Total vs. proximal gastrectomy for proximal gastric cancer:a systematic review and meta-analysis[J].Hepatogastroenterology,2012,59(114):633-640. |
43. | Chen XZ,Yang K,Liu J,et al.Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer[J].World J Gastroenterol,2011,17(40):4542-4544. |
44. | 胡建昆,陈心足.食管胃结合部腺癌围手术期放化疗合理应用及评价[J].中国实用外科杂志,2012,32(4):303-306. |
45. | Schuhmacher C,Gretschel S,Lordick F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218. |
46. | Hu JK,Li CM,Chen XZ,et al.The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma:A systematic review of published randomi-zed controlled trials[J].J Chemother,2007,19(4):359-375. |
47. | Paoletti X,Oba K,Burzykowski T,et al.Benefit of adjuvant chemotherapy for resectable gastric cancer:a meta-analysis[J].JAMA,2010,303(17):1729-1737. |
48. | National Comprehensive Cancer Network.Gastric Cancer (Inclu-ding cancer in the proximal 5 cm of the stomach) Version 2.2013.NCCN Clinical Practice Guilelines in Oncology 2013[EB/OL].http://www.nccn.org. |
49. | Fiori E,Lamazza A,Demasi E,et al.Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pylo-ric cancer.Systematic review of the literature and final results of a prospective study.The point of view of a surgical group[J].Am J Surg,2013,206(2):210-217. |
- 1. 胡建昆,陈心足.进展期胃癌治疗方式合理选择及评价[J].中国实用外科杂志,2011,31(8):720-722.
- 2. 胡建昆,陈心足.胃癌多学科协作诊疗模式现状[J].中国普外基础与临床杂志,2012,19(1):1-3.
- 3. Hu B,El Hajj N,Sittler S,et al.Gastric cancer:Classification,histology and application of molecular pathology[J].J Gastrointest Oncol,2012,3(3):251-261.
- 4. 何裕隆.胃癌病理分型研究进展[J].中国实用外科杂志,2005,25(7):438-440.
- 5. Santiago JM,Sasako M,Osorio J.TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer.Tow-ards simplicity and standardisation in the management of gastric cancer[J].Cir Esp,2011,89(5):275-281.
- 6. Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14(2):113-123.
- 7. Liang YX,Guo HH,Deng JY,et al.Impact of intraoperative blood loss on survival after curative resection for gastric cancer[J].World J Gastroenterol,2013,19(33):5542-5550.
- 8. Yang B,Wu G,Wang X,et al.Discussion of modifying stage Ⅳ gastric cancer based on Borrmann classification[J].Tumour Biol,2013,34(3):1485-1491.
- 9. Sun XC,Lin J,Ju AH.Treatment of Borrmann type Ⅳ gastric cancer with a neoadjuvant chemotherapy combination of docetaxel,cisplatin and 5-fluorouracil/leucovorin[J].J Int Med Res,2011,39(6):2096-2102.
- 10. Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.
- 11. Sasako M,Sano T,Yamamoto S,et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial[J].Lancet Oncol,2006,7(8):644-651.
- 12. Mine S,Sano T,Hiki N,et al.Proximal margin length with trans-hiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction[J].Br J Surg,2013,100(8):1050-1054.
- 13. Lauren P.The two histological main types of gastric carcinoma:Diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification[J].Acta Pathol Microbiol Scand,1965,64:31-49.
- 14. Lauwers GY,Carneiro F,Graham DY.Gastric carcinoma[A]//Bowman FT,Carneiro F,Hruban RH,eds.Classification of tumours of the digestive system[M].Lyon:IARC,2010.In press.
- 15. 李忠武,曹登峰.胃癌病理分型与临床个体化治疗——问题与展望[J].中国医学前沿杂志:电子版,2012,4(5):15-20.
- 16. Liu L,Wang ZW,Ji J,et al.A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma[J].Anticancer Agents Med Chem,2013,13(2):227-234.
- 17. Qiu MZ,Cai MY,Zhang DS,et al.Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China[J].J Transl Med,2013,11:58.
- 18. Lorenzen S,Blank S,Lordick F,et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol,2012,19(7):2119-2127.
- 19. Becker K,Langer R,Reim D,et al.Significance of histopatho-logical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas:a summary of 480 cases[J].Ann Surg,2011,253(5):934-939.
- 20. Kucukoner M,Isikdogan A,Arpaci E,et al.Adjuvant chemora-diation for gastric cancer:multicentric study of the Anatolian Soc-iety of Medical Oncology[J].Hepatogastroenterology,2012,59(119):2343-2347.
- 21. Kucukoner M,Arpaci E,Isikdogan A,et al.Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy[J].Neoplasma,2013,60(1):19-25.
- 22. Yonemura Y,Ninomiya I,Yamaguchi A,et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer[J].Cancer Res,1991,51(3):1034-1038.
- 23. Kataoka Y,Okabe H,Yoshizawa A,et al.HER2 expression and its clinicopathological features in resectable gastric cancer[J].Gastric Cancer,2013,16(1):84-93.
- 24. Aizawa M,Nagatsuma AK,Kitada K,et al.Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population[J].Gastric Cancer,2013 Feb 22.[Epub ahead of print].
- 25. Zhou F,Li N,Jiang W,et al.Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curati-vely resected gastric cancer after the ToGA clinical trial[J].World J Surg Oncol,2012,10:274.
- 26. Jorgensen JT.Targeted HER2 treatment in advanced gastric cancer[J].Oncology,2010,78(1):26-33.
- 27. Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
- 28. Tanner M,Hollmen M,Junttila TT,et al.Amplification of HER-2 in gastric carcinoma:association with Topoisomerase Ⅱalpha gene amplification,intestinal type,poor prognosis and sensitivity to trastuzumab[J].Ann Oncol,2005,16(2):273-278.
- 29. Fan XS,Chen JY,Li CF,et al.Differences in HER2 over-exp-ression between proximal and distal gastric cancers in the Chinese population[J].World J Gastroenterol,2013,19(21):3316-3323.
- 30. Marx AH,Tharun L,Muth J,et al.HER-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2009,40(6):769-777.
- 31. Jorgensen JT,Hersom M.HER2 as a prognostic marker in gastric cancer:a systematic analysis of data from the literature[J].J Cancer,2012,3:137-144.
- 32. Okines AF,Cunningham D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949-1959.
- 33. Okines AF,Cunningham D.Trastuzumab:a novel standard opt-ion for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer[J].Therap Adv Gastroenterol,2012,5(5):301-318.
- 34. Rüschoff J,Hanna W,Bilous M,et al.HER2 testing in gastric cancer:a practical approach[J].Mod Pathol,2012,25(5):637-650.
- 35. Sun Z,Wang ZN,Zhu Z,et al.Evaluation of the seventh edit-ion of American Joint Committee on Cancer TNM staging system for gastric cancer:results from a Chinese monoinstitutional study[J].Ann Surg Oncol,2012,19(6):1918-1927.
- 36. Reim D,Loos M,Vogl F,et al.Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer:the Western experience of patients treated in a single-center European institution[J].J Clin Oncol,2013,31(2):263-271.
- 37. Yoon HM,Ryu KW,Nam BH,et al.Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer?[J].J Am Coll Surg,2012,214(1):88-96.
- 38. Strong VE,D'Amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66.
- 39. Isomoto H,Shikuwa S,Yamaguchi N,et al.Endoscopic submu-cosal dissection for early gastric cancer:a large-scale feasibility study[J].Gut,2009,58(3):331-336.
- 40. Chen XZ,Hu JK,Yang K,et al.Short-term evaluation of lapar-oscopy-assisted distal gastrectomy for predictive early gastric cancer:a meta-analysis of randomized controlled trials[J].Surg Laparosc Endosc Percutan Tech,2009,19(4):277-284.
- 41. Chen XZ,Li YY,Hu JK,et al.Spread and development of laparoscopic surgery for gastric tumors in mainland China:initial experiences[J].Hepatogastroenterology,2012,59(114):654-658.
- 42. Wen L,Chen XZ,Wu B,et al.Total vs. proximal gastrectomy for proximal gastric cancer:a systematic review and meta-analysis[J].Hepatogastroenterology,2012,59(114):633-640.
- 43. Chen XZ,Yang K,Liu J,et al.Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer[J].World J Gastroenterol,2011,17(40):4542-4544.
- 44. 胡建昆,陈心足.食管胃结合部腺癌围手术期放化疗合理应用及评价[J].中国实用外科杂志,2012,32(4):303-306.
- 45. Schuhmacher C,Gretschel S,Lordick F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218.
- 46. Hu JK,Li CM,Chen XZ,et al.The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma:A systematic review of published randomi-zed controlled trials[J].J Chemother,2007,19(4):359-375.
- 47. Paoletti X,Oba K,Burzykowski T,et al.Benefit of adjuvant chemotherapy for resectable gastric cancer:a meta-analysis[J].JAMA,2010,303(17):1729-1737.
- 48. National Comprehensive Cancer Network.Gastric Cancer (Inclu-ding cancer in the proximal 5 cm of the stomach) Version 2.2013.NCCN Clinical Practice Guilelines in Oncology 2013[EB/OL].http://www.nccn.org.
- 49. Fiori E,Lamazza A,Demasi E,et al.Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pylo-ric cancer.Systematic review of the literature and final results of a prospective study.The point of view of a surgical group[J].Am J Surg,2013,206(2):210-217.
-
Previous Article
我国胸心血管外科发展现状与趋势——中华医学会第13次全国胸心血管外科学术会议热点解读 -
Next Article
我国胸心血管外科发展现状与趋势——中华医学会第13次全国胸心血管外科学术会议热点解读